GoodRx (NASDAQ:GDRX) Given New $6.00 Price Target at Morgan Stanley

GoodRx (NASDAQ:GDRX) had its target price decreased by equities researchers at Morgan Stanley from $7.00 to $6.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has an “equal weight” rating on the stock. Morgan Stanley’s target price would indicate a potential upside of 37.30% from the company’s current price.

Other equities research analysts have also issued reports about the company. Barclays dropped their price target on GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Monday, November 11th. Mizuho began coverage on shares of GoodRx in a research report on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 target price on the stock. Finally, Citigroup decreased their price target on shares of GoodRx from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, five have given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, GoodRx presently has an average rating of “Moderate Buy” and a consensus target price of $8.37.

GoodRx Stock Performance

Shares of GDRX opened at $4.37 on Tuesday. GoodRx has a one year low of $4.09 and a one year high of $9.26. The company has a 50-day simple moving average of $5.43 and a two-hundred day simple moving average of $7.02. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. The firm has a market capitalization of $1.67 billion, a PE ratio of -145.67, a price-to-earnings-growth ratio of 3.54 and a beta of 1.29.

Institutional Trading of GoodRx

Institutional investors and hedge funds have recently modified their holdings of the business. Liontrust Investment Partners LLP purchased a new stake in shares of GoodRx during the second quarter valued at $520,000. Legato Capital Management LLC bought a new position in GoodRx during the 2nd quarter valued at about $805,000. Picton Mahoney Asset Management boosted its holdings in shares of GoodRx by 24.3% during the 2nd quarter. Picton Mahoney Asset Management now owns 607,090 shares of the company’s stock valued at $4,736,000 after acquiring an additional 118,703 shares during the last quarter. ClariVest Asset Management LLC grew its stake in shares of GoodRx by 27.4% in the second quarter. ClariVest Asset Management LLC now owns 195,722 shares of the company’s stock worth $1,527,000 after acquiring an additional 42,097 shares during the period. Finally, American Century Companies Inc. purchased a new position in shares of GoodRx during the second quarter valued at approximately $18,183,000. Institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.